TScan Therapeutics News

Express News | HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target

Benzinga07:23 ET

Buy Rating Affirmed: TScan Therapeutics' Innovative TCR-T Therapy and Strategic Milestones Promising for 2024

TipRanks06:27 ET

TScan Therapeutics First Quarter 2024 Earnings: Misses Expectations

Yahoo Finance06:16 ET

Express News | TScan Therapeutics Inc. : Barclays Raises Target Price to $14 From $9

Reuters06:15 ET

Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)

TipRanks19:00 ET

Promising Clinical Results and Robust Financial Position Warrant a Buy Rating for TScan Therapeutics

TipRanksMay 13 09:25 ET

TScan Therapeutics | 10-Q: Quarterly report

SEC announcementMay 13 07:34 ET · Announcements

Express News | TScan Therapeutics' Existing Cash Resources Of $162.8M Along With The $161.4M Net Proceeds Received From Its April 2024 Underwritten Public Offering Will Provide Cash Runway Into The Fourth Quarter Of 2026

BenzingaMay 13 07:07 ET

Express News | TScan Therapeutics Inc - Closed Upsized Underwritten Public Offering With Gross Proceeds of $167.8 Mln, Extending Runway Into Q4 of 2026

ReutersMay 13 07:06 ET

Express News | TScan Therapeutics Inc - First Patient Dosed in Phase 1 Clinical Trial for Treatment of Solid Tumors; Initial Data Anticipated in 2024

ReutersMay 13 07:06 ET

Express News | TScan Therapeutics Q1 2024 GAAP EPS $(0.32) Misses $(0.26) Estimate, Sales $566.000 Miss $3.975M Estimate

BenzingaMay 13 07:05 ET

Express News | TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

ReutersMay 13 07:00 ET

TScan Therapeutics 1Q Loss/Shr 32c >TCRX

TScan Therapeutics 1Q Loss/Shr 32c >TCRX

Dow JonesMay 13 07:00 ET

Express News | Needham Reiterates Buy on TScan Therapeutics, Maintains $11 Price Target

BenzingaMay 13 06:24 ET

Express News | TScan Therapeutics Doses First Patient In Phase 1 Clinical Trial Evaluating TCR-T Therapy For Treatment Of Solid Tumors

BenzingaMay 9 07:05 ET

Express News | TScan Therapeutics Inc - on-Track to Report Initial Data From Solid Tumor Clinical Trial in 2024

ReutersMay 9 07:03 ET

Express News | TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Tcr-T Therapy for the Treatment of Solid Tumors

ReutersMay 9 07:00 ET

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies

GlobeNewswireApr 24 16:05 ET

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies

GlobeNewswireApr 24 11:03 ET

Unveiling 4 Analyst Insights On TScan Therapeutics

TScan Therapeutics (NASDAQ:TCRX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent

BenzingaApr 23 14:01 ET